Neoadjuvant Percutaneous 4-Hydroxytamoxifen Decreases Breast Tumoral Cell Proliferation: A Prospective Controlled Randomized Study Comparing Three Doses of 4-Hydroxytamoxifen Gel to Oral Tamoxifen

• Published in: Journal of clinical oncology Vol. 23; no. 13; pp. 2980 - 2987
• Main Authors: ROUANET, Philippe, LINARES-CRUZ, Gustavo, MAUDELONDE, Thierry, DRAVET, Francois, PONJOL, Sylvain, GOURGOU, Sophie, SIMONY-LAFONTAINE, Joelle, GRENIER, Jean, KRAMAR, Andrew, GIRAULT, Jean, LE NESTOUR, Elisabeth
• Format: Journal Article
• Language: English
• Published: Baltimore, MD American Society of Clinical Oncology 01.05.2005; Lippincott Williams & Wilkins
• Subjects: Administration, Cutaneous; Administration, Oral; Administration, Topical; Adult; Aged; Antineoplastic Agents, Hormonal - administration & dosage; Antineoplastic Agents, Hormonal - adverse effects; Antineoplastic Agents, Hormonal - therapeutic use; Apoptosis; Biological and medical sciences; Biopsy; Breast Neoplasms - drug therapy; Breast Neoplasms - pathology; Cell Proliferation; Dose-Response Relationship, Drug; Estrogen Antagonists - administration & dosage; Estrogen Antagonists - adverse effects; Estrogen Antagonists - therapeutic use; Female; Humans; Medical sciences; Middle Aged; Neoadjuvant Therapy; Postmenopause; Receptors, Estrogen - agonists; Receptors, Estrogen - analysis; Tamoxifen - administration & dosage; Tamoxifen - adverse effects; Tamoxifen - analogs & derivatives; Tamoxifen - therapeutic use; Tumors; Antineoplastic agent; Cell proliferation; Antiestrogen; Oral administration; Antihormone; Tamoxifene; Percutaneous route; Prospective; Randomization; Cancerology; Tumor; Mammary gland; Non steroid compound; Dose; Comparative study

Two chemoprevention randomized studies using tamoxifen showed drug efficacy; however, adverse effects such as hot flushes, endometrial cancer, and above all, thromboembolism, remain a problem. 4 hydroxytamoxifen (4-OHT) is a very active metabolite of tamoxifen. This randomized study was designed to...